PR
Prime Medicine, Inc.
PRME · NASDAQ
$3.12 +0.00% (+$0.00)
1M -7.96%
Market Cap $567.1M
P/E Ratio -
Div. Yield -
ROE 188.27%
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 139.24x
P/B 14.25x
P/E N/A
Growth
0 /100
Declining Book val. growth 27.43%
EPS growth N/A
Rev. growth N/A
Profitability
0 /100
Weak Gross margin 1,025.61%
Net margin 4,613.11%
FCF margin 3,850.92%
Quality
0 /100
Poor ROIC 86.83%
ROE 188.27%
Asset turnover 0.02x
Debt
33 /100
High Debt/Equity 2.83x
Current ratio 3.05x
Int. coverage N/A
Stability
22 /100
Unstable Beta 2.35x
EPS volatility 40.70%
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre PRME
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Allan Reine
Employees
146
Headquarters
Cambridge
Evenimente viitoare
06 NOV.
Earnings
Upcoming earnings report